SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule ...
A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...
Impressive listing gains during the post-pandemic bull run have fueled investor confidence, prompting HNIs to allocate funds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback